NCT00359021View on ClinicalTrials.gov

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

PHASE3CompletedINTERVENTIONAL

Enrollment

503

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

HIV-1

Interventions

DRUG

TMC125

200 mg twice daily until commercially available

Trial Locations (72)

Unknown

Phoenix

Little Rock

Beverly Hills

Long Beach

Los Angeles

Palm Springs

San Diego

San Francisco

Denver

Washington D.C.

Fort Lauderdale

Fort Laudersale

Miami

North Miami Beach

Safety Harbor

Tampa

Chicago

Boston

Camden

Newark

New York

The Bronx

Durham

Winston-Salem

Portland

Philadelphia

Austin

Dallas

Houston

Longview

Annandale

Seattle

Buenos Aires

Córdoba

Neuquén

San Juan Bautista

Darlinghurst

Antwerp

Liège

Curitiba

Rio de Janeiro

Salvador

São Paulo

Calgary

Toronto

Montreal

Toronto

Providencia

Santiago

Bordeaux

Le Kremlin-Bicêtre

Lyon

Marseille

Paris

Rennes

Toulouse

Tourcoing

Villejuif

Berlin

Essen

Hamburg

Mannheim

München

Mex Ctity

Mexico City

Panama City

San Juan

Barcelona

Madrid

Valencia

Bangkok

Khon Kaen

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00359021 - An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216). | Biotech Hunter | Biotech Hunter